PD-1 Protein, Human, Recombinant (ECD, His & hFc Tag)


PD-1 Protein, Human, Recombinant (ECD, His & hFc Tag): Product Information

> 97 % as determined by SDS-PAGE
< 1.0 EU per μg of the protein as determined by the LAL method
Measured by its binding ability in a functional ELISA. Immobilized recombinant human PD-L2 at 1 μg/ml (100ul/well) can bind human PD1 / Fc chimera with a linear range of 7.8-1000 ng/ml.
Protein Construction
A DNA sequence encoding the extracellular domain (Met 1-Gln 167) of human PD1 (NP_005009.2) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus.
Expressed Host
HEK293 Cells
Predicted N Terminal
Leu 25
Molecule Mass
The recombinant human PD1/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 390 amino acids and has a calculated molecular mass of 43.84 kDa. As a result of glycosylation, human PD1/Fc monomer migrates as an approximately 55-66 kDa protein in SDS-PAGE under reducing conditions.
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

PD-1 Protein, Human, Recombinant (ECD, His & hFc Tag): Images

Measured by its binding ability in a functional ELISA. Immobilized recombinant human PD-L2 at 1 μg/ml (100 μl/well) can bind human PD1 / Fc chimera with a linear range of 7.8-1000 ng/ml.

PD-1 Protein, Human, Recombinant (ECD, His & hFc Tag): Synonyms

CD279 Protein, Human; hPD-1 Protein, Human; hPD-l Protein, Human; hSLE1 Protein, Human; PD-1 Protein, Human; PD1 Protein, Human; SLEB2 Protein, Human

PD-1 Background Information

Programmed cell death 1, also known as PDCD1, is a type I transmembrane glycoprotein, and is an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. PD1 has been suggested to be involved in lymphocyte clonal selection and peripheral tolerance, and thus contributes to the prevention of autoimmune diseases. Furthermore, PD1 is shown to be a regulator of virus-specific CD8+ T cell survival in HIV infection. As a cell surface molecule, PDCD1 regulates the adaptive immune response. Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function.
Full Name
programmed cell death 1
  • James ES, et al. (2005) PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun. 6(5): 430-7.
  • Okazaki T, et al. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 19(7): 813-24.
  • del Rio ML, et al. (2008) PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int. 21(11): 1015-28.
  • Riley JL.(2009) PD-1 signaling in primary T cells. Immunol Rev. 229(1): 114-25.
  • Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
    Zhang, S;Zhang, M;Wu, W;Yuan, Z;Tsun, A;Wu, M;Chen, B;Li, J;Miao, X;Miao, X;Liu, X;Yu, D;Liu, J;
    Antibody Therapeutics
    PK analysis
  • Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors
    Yuan, X;Sun, Z;Yuan, Q;Hou, W;Liang, Q;Wang, Y;Mo, W;Wang, H;Yu, M;
    Invest New Drugs
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.